BRPI0607088A2 - derivados de tetrahidrofurano heterocìclico tetracìclico como inibidores de 5ht2 no tratamento de distúrbios cns - Google Patents
derivados de tetrahidrofurano heterocìclico tetracìclico como inibidores de 5ht2 no tratamento de distúrbios cnsInfo
- Publication number
- BRPI0607088A2 BRPI0607088A2 BRPI0607088-4A BRPI0607088A BRPI0607088A2 BR PI0607088 A2 BRPI0607088 A2 BR PI0607088A2 BR PI0607088 A BRPI0607088 A BR PI0607088A BR PI0607088 A2 BRPI0607088 A2 BR PI0607088A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- tetrahydrofuran derivatives
- inhibitors
- receptors
- tetracyclic heterocyclic
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 heterocyclic tetrahydrofuran derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 abstract 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 abstract 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 abstract 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 abstract 1
- 108050004812 Dopamine receptor Proteins 0.000 abstract 1
- 102000015554 Dopamine receptor Human genes 0.000 abstract 1
- 101150104779 HTR2A gene Proteins 0.000 abstract 1
- 101150013372 Htr2c gene Proteins 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000966 norepinephrine reuptake Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
DERIVADOS DE TETRAHIDROFURANO HETEROCìCLICO TETRACICLICO COMO INIBIDORES DE 5HT2 NO TRATAMENTO DE DISTúRBIOS CNS. A presente invenção refere-se a novos derivados de tetrahidrofurano heterocíclico tetracíclico substituidos com afinidades de ligação por receptores de serotonina, em particular receptores 5-HT2A e 5-HT2ç e por receptores de dopamina, em particular receptores de dopamina D2 e com propriedades de inibição da recaptação de norepinefrina, composições farmacêuticas compreendendo os compostos de acordo com a invenção, o uso dos mesmos como um medicamento, em particular para a prevenção e/ou tratamento de uma série de distúrbios psiquiátricos e neurológicos, em particular determinados distúrbios psicóticos, cardiovasculares e gastrocinéticos e processos para sua produção. Os compostos de acordo com a invenção podem ser representados pela Fórmula geral (1): e compreendem também os sais de adição de base ou ácido farmaceuticamente aceitáveis dos mesmos, as formas estereoquimicamente isoméricas dos mesmos, a forma de N-óxido dos mesmos e pró-fármacos dos mesmos, em que todos os substituintes são definido conforme na reivindicação 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05100547 | 2005-01-27 | ||
| PCT/EP2006/050444 WO2006079637A1 (en) | 2005-01-27 | 2006-01-25 | Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0607088A2 true BRPI0607088A2 (pt) | 2009-08-04 |
Family
ID=34938591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607088-4A BRPI0607088A2 (pt) | 2005-01-27 | 2006-01-25 | derivados de tetrahidrofurano heterocìclico tetracìclico como inibidores de 5ht2 no tratamento de distúrbios cns |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7915249B2 (pt) |
| EP (1) | EP1846415B1 (pt) |
| JP (1) | JP4937141B2 (pt) |
| KR (1) | KR101332218B1 (pt) |
| CN (1) | CN101107254B (pt) |
| AU (1) | AU2006209397B2 (pt) |
| BR (1) | BRPI0607088A2 (pt) |
| CA (1) | CA2595170C (pt) |
| EA (1) | EA013595B1 (pt) |
| ES (1) | ES2391780T3 (pt) |
| MX (1) | MX2007009092A (pt) |
| NZ (1) | NZ556272A (pt) |
| WO (1) | WO2006079637A1 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1558582T3 (pl) | 2003-07-22 | 2006-05-31 | Arena Pharm Inc | Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem |
| SA05260357B1 (ar) | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به |
| EA016675B1 (ru) | 2006-05-18 | 2012-06-29 | Арена Фармасьютикалз, Инк. | Способы получения фенилпиразолов и кристаллическая форма производного фенилпиразола |
| EP3395816A1 (en) | 2006-05-18 | 2018-10-31 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| WO2007136703A1 (en) | 2006-05-18 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| JP5393677B2 (ja) | 2007-08-15 | 2014-01-22 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体 |
| WO2009105507A2 (en) * | 2008-02-19 | 2009-08-27 | Adolor Corporation | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| SMT201800199T1 (it) | 2008-10-28 | 2018-05-02 | Arena Pharm Inc | Composizioni di un modulatore dei recettori della serotonina 5-ht2a utili per il trattamento di disturbi correlati a esso |
| WO2011075596A1 (en) | 2009-12-18 | 2011-06-23 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
| RU2018103338A (ru) | 2015-07-15 | 2019-08-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием |
| JP7281563B2 (ja) | 2019-06-12 | 2023-05-25 | ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ | ペルオキシエステルを生成するためのプロセス |
| EP3983368B1 (en) | 2019-06-12 | 2023-08-02 | Nouryon Chemicals International B.V. | Process for the production of diacyl peroxides |
| WO2020249692A1 (en) * | 2019-06-12 | 2020-12-17 | Nouryon Chemicals International B.V. | Method for isolating carboxylic acid from an aqueous side stream |
| HUE063677T2 (hu) | 2019-06-12 | 2024-01-28 | Nouryon Chemicals Int Bv | Eljárás diacil-peroxidok elõállítására |
| ES2963382T3 (es) | 2019-06-12 | 2024-03-26 | Nouryon Chemicals Int Bv | Proceso para la producción de peróxidos de diacilo |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH615928A5 (pt) | 1975-06-18 | 1980-02-29 | Sandoz Ag | |
| CS200271B1 (cs) | 1979-02-08 | 1980-09-15 | Miroslav Rajsner | Derivát 4,5-dihydrothieno (2,3-b)-l-benzothiepinu a jeho eoli |
| CS217949B1 (cs) | 1981-08-14 | 1983-01-28 | Miroslav Protiva | Derivát 4,5-dihydrothieno(2,3-b)-1-benzothiepinu a jeho soli |
| PL158223B1 (en) | 1989-06-09 | 1992-08-31 | Method for mnufacturing 4-(1-methyl-4-pirperidilidene)-9,10-dihydro--benso(4,5) cyclohepta (1,2) thiophen-10-on | |
| CN1116291C (zh) * | 1996-04-12 | 2003-07-30 | 詹森药业有限公司 | 取代的四环四氢呋喃衍生物 |
| ATE222911T1 (de) * | 1996-04-12 | 2002-09-15 | Janssen Pharmaceutica Nv | Isoxazolidine derivate |
| UA52778C2 (uk) * | 1997-10-10 | 2003-01-15 | Янссен Фармацевтика Н.В. | Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі |
| UA79248C2 (en) | 2001-11-09 | 2007-06-11 | Janssen Pharmaceutica Nv | Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives |
| DE60203937T2 (de) | 2001-12-07 | 2006-05-11 | Janssen Pharmaceutica N.V. | Herstellung von trans-kondensierte 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivaten |
| EP1824820A2 (en) * | 2004-12-07 | 2007-08-29 | Janssen Pharmaceutica N.V. | Substituted tetracyclic tetrahydrofuran,pyrrolidine and tetrahydrothiophene derivatives |
-
2006
- 2006-01-25 EP EP06704282A patent/EP1846415B1/en active Active
- 2006-01-25 MX MX2007009092A patent/MX2007009092A/es active IP Right Grant
- 2006-01-25 NZ NZ556272A patent/NZ556272A/en not_active IP Right Cessation
- 2006-01-25 US US11/814,432 patent/US7915249B2/en not_active Expired - Fee Related
- 2006-01-25 KR KR1020077019160A patent/KR101332218B1/ko not_active Expired - Fee Related
- 2006-01-25 JP JP2007552640A patent/JP4937141B2/ja not_active Expired - Fee Related
- 2006-01-25 ES ES06704282T patent/ES2391780T3/es active Active
- 2006-01-25 WO PCT/EP2006/050444 patent/WO2006079637A1/en active Application Filing
- 2006-01-25 EA EA200701583A patent/EA013595B1/ru not_active IP Right Cessation
- 2006-01-25 AU AU2006209397A patent/AU2006209397B2/en not_active Ceased
- 2006-01-25 CA CA2595170A patent/CA2595170C/en not_active Expired - Fee Related
- 2006-01-25 CN CN2006800032542A patent/CN101107254B/zh not_active Expired - Fee Related
- 2006-01-25 BR BRPI0607088-4A patent/BRPI0607088A2/pt not_active IP Right Cessation
-
2011
- 2011-02-16 US US13/028,596 patent/US8404729B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2391780T3 (es) | 2012-11-29 |
| US20110144094A1 (en) | 2011-06-16 |
| KR101332218B1 (ko) | 2013-11-25 |
| JP2008528548A (ja) | 2008-07-31 |
| CN101107254B (zh) | 2010-12-08 |
| WO2006079637A1 (en) | 2006-08-03 |
| EP1846415B1 (en) | 2012-08-01 |
| EA013595B1 (ru) | 2010-06-30 |
| EA200701583A1 (ru) | 2008-04-28 |
| KR20070098938A (ko) | 2007-10-05 |
| CA2595170A1 (en) | 2006-08-03 |
| AU2006209397A1 (en) | 2006-08-03 |
| US7915249B2 (en) | 2011-03-29 |
| JP4937141B2 (ja) | 2012-05-23 |
| US8404729B2 (en) | 2013-03-26 |
| EP1846415A1 (en) | 2007-10-24 |
| WO2006079637A8 (en) | 2007-08-16 |
| MX2007009092A (es) | 2007-09-12 |
| AU2006209397B2 (en) | 2011-04-07 |
| US20080108599A1 (en) | 2008-05-08 |
| CN101107254A (zh) | 2008-01-16 |
| CA2595170C (en) | 2014-08-05 |
| NZ556272A (en) | 2009-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0607088A2 (pt) | derivados de tetrahidrofurano heterocìclico tetracìclico como inibidores de 5ht2 no tratamento de distúrbios cns | |
| TW200716120A (en) | Pyrazolo-pyrimidine derivatives as mGluR2 antagonists | |
| GEP20125566B (en) | Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | |
| NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
| BRPI0817242A8 (pt) | compostos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano, processo para a sua manufatura e composições farmacêuticas que os contêm | |
| DK1856090T3 (da) | Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
| ECSP088405A (es) | Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer | |
| BR122013028005B8 (pt) | compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos | |
| WO2009013212A3 (en) | Dual modulators of 5-ht2a and d3 receptors | |
| BRPI0510453A (pt) | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central | |
| MX2009010505A (es) | Derivados de piridina y pirimidina como antagonistas de mglur2. | |
| MX2007010400A (es) | Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| WO2009118765A3 (en) | Novel monoamine re-uptake inhibitor | |
| WO2010011811A3 (en) | 3-(phenoxyphenylmethyl)pyrrolidine compounds | |
| UA98772C2 (ru) | Производные циклопропиламина как модуляторы н3-гистаминового рецептора | |
| BRPI0606881A2 (pt) | composto derivado de dihidroimidazotiazol, composição farmacêutica, seu uso e processo para a sua produção | |
| BRPI0909737A2 (pt) | compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos | |
| MX2010001195A (es) | Derivados de benzoil-peperidina como moduladores dobles de los receptores 5-ht2a y d3. | |
| DE602004007658D1 (de) | Indolderivate mit verbesserter antipsychotischer wirkung | |
| MX2009002906A (es) | Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia. | |
| WO2006061392A3 (en) | Substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives | |
| EA200702626A1 (ru) | Новые замещённые тетрациклические производные тетрагидрофурана, пирролидина и тетрагидротиофена и их применение в качестве лекарственного средства | |
| TW200612899A (en) | Novel tetracyclic tetrahydrofuran derivatives | |
| ATE460411T1 (de) | Neue tetracyclische tetrahydrofuran-derivate mit cyclischer aminseitenkette |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2498 DE 21-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |